EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Efficacy and safety of sepiapterin versus sapropterin in people living with phenylketonuria: a plain language summary of the AMPLIPHY trial

Maria Giżewska, Laura Guilder, Sarah Gallagher, Anita Inwood

Journal of Comparative Effectiveness Research · 11.11.2026

DOI: 10.57264/cer-2026-0115 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Comparative Effectiveness Research, online erschienen am 11.11.2026. Verfasst von Maria Giżewska und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Rare Diseases & Metabolic Medicine, Pomeranian Medical University in Szczecin, Szczecin, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

What is this summary about? This summary is about a clinical trial called AMPLIPHY. AMPLIPHY was a trial that compared two treatments, sepiapterin and sapropterin, to see how well they worked in children and adults living with phenylketonuria (PKU). PKU is a rare genetic condition where the body cannot properly break down phenylalanine (Phe), which is an amino acid found in many foods. If people living with PKU are not treated, Phe levels build up in the body, which can affect brain development, thinking skills and behaviour. If left untreated for a long time, this may cause symptoms such as seizures, rashes and problems with movement. A key goal of PKU treatment is to keep blood Phe levels within a target range to avoid these effects. What happened in the AMPLIPHY trial? In the AMPLIPHY trial, the researchers wanted to see how well sepiapterin worked in people living with PKU when compared with sapropterin, an alternative treatment for PKU, and to compare the safety of the treatments. The AMPLIPHY trial had two parts: During Part 1, the participants took sepiapterin for 2 weeks to find out whether it decreased their Phe levels. - Participants whose blood Phe levels decreased by at least 20% were classed as responsive to sepiapterin and could continue to Part 2. - Participants whose blood Phe levels decreased by less than 20% did not continue to Part 2. During Part 2: - The participants took either sepiapterin or sapropterin for the first 4 weeks followed by 4 weeks of the other treatment. What were the results? During Part 1, the researchers found that most people benefited from sepiapterin. Specifically, 82% of participants (67 out of 82) had a reduction in blood Phe levels of at least 20%, and 76% of participants (62 out of 82) had a reduction of at least 30%. During Part 2, the researchers found that sepiapterin lowered blood Phe levels by 70% more than sapropterin did. There were no adverse events that were considered serious or that stopped anyone from taking treatment or participating in the trial. What do the results of the trial mean? How well did the treatments work: these results showed that sepiapterin lowered blood Phe levels more than sapropterin in children and adults with PKU. What were the safety findings: sepiapterin was well tolerated, with no unexpected side effects or safety concerns identified. ClinicalTrials.gov, NCT number: NCT05099640

Schlagwörter

Stichwörter der Autor:innen

phenylketonuriaplain language summarysapropterinsepiapterin

Autor:innen und Institutionen

  • Department of Pediatrics, Rare Diseases & Metabolic Medicine, Pomeranian Medical University in Szczecin, Szczecin, Poland.
  • Division of Clinical & Metabolic Genetics, Department of Paediatrics, University of Toronto & The Hospital for Sick Children, Toronto, ON, Canada.
  • National PKU Alliance, Roanoke, VA, USA, & patient caregiver.
  • Department of Metabolic Medicine, Queensland Lifespan Metabolic Medicine Service, Queensland Children's Hospital, Brisbane, QLD, Australia.

Zitieren

APA

Giżewska, M., Guilder, L., Gallagher, S., & Inwood, A. (2026). Efficacy and safety of sepiapterin versus sapropterin in people living with phenylketonuria: a plain language summary of the AMPLIPHY trial. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2026-0115

Vancouver

Giżewska M, Guilder L, Gallagher S, Inwood A. Efficacy and safety of sepiapterin versus sapropterin in people living with phenylketonuria: a plain language summary of the AMPLIPHY trial. Journal of Comparative Effectiveness Research. 2026. doi:10.57264/cer-2026-0115

BibTeX
@article{Giewska2026,
  author = {Giżewska, Maria and Guilder, Laura and Gallagher, Sarah and Inwood, Anita},
  title = {Efficacy and safety of sepiapterin versus sapropterin in people living with phenylketonuria: a plain language summary of the AMPLIPHY trial},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2026},
  doi = {10.57264/cer-2026-0115}
}
Kostenlos starten →